EUVIMEDEUVIMED entdecken
Übersichtsarbeit

How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation

Tali Shafat, Ella J Ariza-Heredia, Marilyne Daher, Roy F Chemaly

Clinical Microbiology and Infection · 2025-05 · 31 (5) · 761-772

DOI: 10.1016/j.cmi.2025.01.033 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology and Infection, 2025-05. Verfasst von Tali Shafat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Elect…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Antiviral Agents, Herpes Simplex, Simplexvirus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Herpes simplex virus (HSV) infection is a clinically significant complication in haematopoietic cell transplant (HCT) recipients. Refractory and resistant (R/R) HSV infections may occur in this patient population, particularly after prolonged exposure to anti-HSV agents. OBJECTIVES: This study aims to provide a comprehensive review of the diagnostic approach and the treatment options for R/R HSV mucocutaneous infections in HCT recipients and to highlight future treatment strategies. SOURCES: We searched the PubMed Central Database and Embase to identify published studies on R/R HSV infections in HCT recipients. We used the search terms "herpes simplex virus," "resistant∗," OR "refractory," "immunocompromised," "immunosuppress∗," and "immunodeficien∗," and screened the results for articles reporting R/R HSV infections among HCT recipients. We chose an HCT recipient with a complicated refractory HSV infection as a representative clinical case. CONTENT: A clear clinical definition of refractory HSV infection is currently not available, which can lead to delays in diagnosis and treatment, negatively impacting patient care. Apart from two small randomized controlled trials in the 1990s that looked at treatment with systemic foscarnet and topical cidofovir in patients living with human immunodeficiency virus, all treatment recommendations for R/R HSV infections are based on observational studies and case reports. The use of alternative treatment options often comes with serious side effects, such as kidney toxicity. This underscores the urgent need for safer and more effective treatment options. Pritelivir, a new oral antiviral medication, is currently being studied in a phase 3 trial for R/R HSV infections in immunocompromised patients. Limited data from the Early Access Program, which allows compassionate use, suggest that pritelivir holds promise as a treatment option for HCT recipients with R/R HSV infections. IMPLICATIONS: The proposed R/R HSV mucocutaneous infection diagnostic and treatment algorithm guides the appropriate management of these difficult-to-treat infections, potentially improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationAntiviral AgentsHerpes SimplexSimplexvirusHumansDrug Resistance, ViralImmunocompromised HostFoscarnet

Stichwörter der Autor:innen

Haematopoietic cell transplantHerpes Simplex VirusImmunosuppressionRefractoryResistance

Substanzen

Antiviral AgentsFoscarnet

Autor:innen und Institutionen

  • Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: tshafat@mdanderson.org.
  • Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Förderung

  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Shafat, T., Ariza-Heredia, E. J., Daher, M., & Chemaly, R. F. (2025). How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation. Clinical Microbiology and Infection, 31(5), 761-772. https://doi.org/10.1016/j.cmi.2025.01.033

Vancouver

Shafat T, Ariza-Heredia EJ, Daher M, Chemaly RF. How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation. Clinical Microbiology and Infection. 2025;31(5):761-772. doi:10.1016/j.cmi.2025.01.033

BibTeX
@article{Shafat2025,
  author = {Shafat, Tali and Ariza-Heredia, Ella J and Daher, Marilyne and Chemaly, Roy F},
  title = {How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation},
  journal = {Clinical Microbiology and Infection},
  year = {2025},
  volume = {31},
  number = {5},
  pages = {761--772},
  doi = {10.1016/j.cmi.2025.01.033}
}
Kostenlos starten →